New potential drug targets discovered for preventing prostate cancer cell growth
In addition to previously discovered enzymes that contribute to prostate cancer cell growth, the new study published by researchers from VTT and the University of Turku identifies four enzymes that regulate arachidonic acid metabolism and reveals that prostate cancer cell growth can be inhibited by preventing the functioning of these enzymes.
The study analysed the prevalence of enzymes involved in arachidonic acid metabolism in hundreds of prostate cancer samples, normal prostate samples, and other healthy tissues. The enzymes with the highest expression in prostate cancer samples were selected for further studies in prostate cancer cells. The scientists discovered that certain enzymes were more prevalent than others in different kinds of prostate cancers. This knowledge can be used to identify different subtypes of prostate cancer in the future. The findings of the study provide valuable new information and can potentially lead to the discovery of new ways to treat prostate cancer.
Original publication
"Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer."; The American Journal of Pathology, Volume 178, Issue 2, Pages 525–536, 2011.
Original publication
"Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer."; The American Journal of Pathology, Volume 178, Issue 2, Pages 525–536, 2011.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.